[go: up one dir, main page]

WO2008106938A3 - Diagnostic et stratification des risques d'une insuffisance cardiaque au moyen de peptides natriurétiques pour des patients nyha i - Google Patents

Diagnostic et stratification des risques d'une insuffisance cardiaque au moyen de peptides natriurétiques pour des patients nyha i Download PDF

Info

Publication number
WO2008106938A3
WO2008106938A3 PCT/DE2008/000357 DE2008000357W WO2008106938A3 WO 2008106938 A3 WO2008106938 A3 WO 2008106938A3 DE 2008000357 W DE2008000357 W DE 2008000357W WO 2008106938 A3 WO2008106938 A3 WO 2008106938A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
nyha
diagnosis
cardiac insufficiency
risk stratification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2008/000357
Other languages
German (de)
English (en)
Other versions
WO2008106938A2 (fr
Inventor
Andreas Bergmann
Nils Morgenthaler
Jana Papassotiriou
Joachim Struck
Stefan Anker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Priority to US12/529,365 priority Critical patent/US8252544B2/en
Priority to JP2009551101A priority patent/JP5584473B2/ja
Priority to ES08734336.4T priority patent/ES2620392T3/es
Priority to EP08734336.4A priority patent/EP2122363B1/fr
Publication of WO2008106938A2 publication Critical patent/WO2008106938A2/fr
Publication of WO2008106938A3 publication Critical patent/WO2008106938A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/325Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

L'invention concerne un procédé de diagnostic et/ou de stratification des risques et/ou de pronostic d'évolution d'une insuffisance cardiaque pour des patients NYHA I, sachant qu'une détermination du marqueur proANP ou NT-proANP, ou respectivement de fragments ou de peptides partiels de ceux-ci, est effectuée parallèlement à une détermination de BNP, proBNP et/ou NT-proBNP sur des patients à examiner.
PCT/DE2008/000357 2007-03-03 2008-03-03 Diagnostic et stratification des risques d'une insuffisance cardiaque au moyen de peptides natriurétiques pour des patients nyha i Ceased WO2008106938A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/529,365 US8252544B2 (en) 2007-03-03 2008-03-03 Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients
JP2009551101A JP5584473B2 (ja) 2007-03-03 2008-03-03 Nyhai患者についての心機能不全の診断および危険性層化のためのナトリウム利尿ペプチドのインビトロ決定
ES08734336.4T ES2620392T3 (es) 2007-03-03 2008-03-03 Diagnóstico y estratificación del riesgo de insuficiencia cardiaca por medio de péptidos natriuréticos para pacientes NYHA I
EP08734336.4A EP2122363B1 (fr) 2007-03-03 2008-03-03 Diagnostic et stratification des risques d'une insuffisance cardiaque au moyen de peptides natriurétiques pour des patients nyha i

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007010834.8 2007-03-03
DE102007010834A DE102007010834A1 (de) 2007-03-03 2007-03-03 Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten

Publications (2)

Publication Number Publication Date
WO2008106938A2 WO2008106938A2 (fr) 2008-09-12
WO2008106938A3 true WO2008106938A3 (fr) 2008-11-20

Family

ID=39638892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2008/000357 Ceased WO2008106938A2 (fr) 2007-03-03 2008-03-03 Diagnostic et stratification des risques d'une insuffisance cardiaque au moyen de peptides natriurétiques pour des patients nyha i

Country Status (7)

Country Link
US (1) US8252544B2 (fr)
EP (2) EP3139173A1 (fr)
JP (1) JP5584473B2 (fr)
CN (2) CN107015009B (fr)
DE (1) DE102007010834A1 (fr)
ES (1) ES2620392T3 (fr)
WO (1) WO2008106938A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628136A1 (fr) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Procédé diagnostic pour des maladies utilisant la copeptin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
WO2007114947A2 (fr) 2006-04-04 2007-10-11 Singulex, Inc. Système et procédés hautement sensibles destinés à une analyse de la troponine
JP5528461B2 (ja) * 2008-10-17 2014-06-25 エフ.ホフマン−ラ ロシュ アーゲー 心不全の評価におけるビグリカンの使用
JP5753159B2 (ja) * 2009-05-05 2015-07-22 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮性機能/機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
EP2440936A4 (fr) 2009-06-08 2013-03-13 Singulex Inc Groupes de biomarqueurs très sensibles
JP5592487B2 (ja) 2009-07-27 2014-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 心不全の評価におけるミメカンの使用
RU2423072C1 (ru) * 2009-11-19 2011-07-10 Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования исхода постгипоксических нарушений сердечно-сосудистой системы у новорожденных
JP5827323B2 (ja) * 2010-06-18 2015-12-02 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング ガン罹患の予測のためのバイオマーカー
WO2012059477A1 (fr) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Évaluation du pronostic et du risque chez des patients se plaignant de manière non spécifique
US10436798B2 (en) 2011-07-28 2019-10-08 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
US9128103B2 (en) * 2011-07-28 2015-09-08 B.R.A.H.M.S. Gmbh Mid-regional pro-atrial natriuretic peptide (pro-ANP) for the identification of patients with atrial fibrillation with an onset of less than 48 hours ago
EP2739974A4 (fr) * 2011-08-05 2015-04-08 Alere San Diego Inc Procédés et compositions de surveillance d'insuffisance cardiaque
US20160147958A1 (en) * 2013-07-26 2016-05-26 Koninklijke Philips N.V. Computerization and visualization of clinical rules and definitions for patient monitoring systems
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046181A1 (fr) * 2002-11-20 2004-06-03 B.R.A.H.M.S Aktiengesellschaft Dosage immunologique sandwich pour detecter des peptides partiels proanp
EP1577673A1 (fr) * 2004-03-15 2005-09-21 F. Hoffmann-La Roche Ag Utilisation des peptides de type BNP et ANP pour évaluer les risques de complications cardiovasculaires due à une surcharge de volume
WO2005124364A1 (fr) * 2004-06-15 2005-12-29 F. Hoffmann-La Roche Ag Utilisation d'hormones cardiaques pour le diagnostic des risques de complications cardiovasculaires dues a une intoxication liee a un medicament cardiotoxique
WO2006087373A1 (fr) * 2005-02-17 2006-08-24 F. Hoffmann-La Roche Ag Utilisation du rapport nt-proanp/nt-probnp pour diagnostiquer des dysfonctionnements cardiaques
EP1901073A1 (fr) * 2006-09-18 2008-03-19 Roche Diagnostics GmbH Des peptides natriurétiques pour la diagnose des complications cardiaques en raison de cathéterisation coronaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305142D0 (en) 1993-03-12 1993-04-28 Medinnova Sf Method
ATE180058T1 (de) 1994-12-09 1999-05-15 Shionogi & Co Sandwich-immunotestverfahren für n-peptide
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
FR2843396B1 (fr) * 2002-08-07 2005-04-15 Bio Rad Pasteur Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
WO2004046194A2 (fr) * 2002-11-18 2004-06-03 Syn X Pharma, Inc. Test elisa polyclone-monoclone pour la detection de probnp a n-terminal
EP1731910A1 (fr) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Utilisation de NT-proANP et NT-proBNP pour le diagnostic de maladies cardiaques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046181A1 (fr) * 2002-11-20 2004-06-03 B.R.A.H.M.S Aktiengesellschaft Dosage immunologique sandwich pour detecter des peptides partiels proanp
EP1577673A1 (fr) * 2004-03-15 2005-09-21 F. Hoffmann-La Roche Ag Utilisation des peptides de type BNP et ANP pour évaluer les risques de complications cardiovasculaires due à une surcharge de volume
WO2005124364A1 (fr) * 2004-06-15 2005-12-29 F. Hoffmann-La Roche Ag Utilisation d'hormones cardiaques pour le diagnostic des risques de complications cardiovasculaires dues a une intoxication liee a un medicament cardiotoxique
WO2006087373A1 (fr) * 2005-02-17 2006-08-24 F. Hoffmann-La Roche Ag Utilisation du rapport nt-proanp/nt-probnp pour diagnostiquer des dysfonctionnements cardiaques
EP1901073A1 (fr) * 2006-09-18 2008-03-19 Roche Diagnostics GmbH Des peptides natriurétiques pour la diagnose des complications cardiaques en raison de cathéterisation coronaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VON HAEHLING ET AL: "Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 50, no. 20, 29 October 2007 (2007-10-29), pages 1973 - 1980, XP022332007, ISSN: 0735-1097 *

Also Published As

Publication number Publication date
EP3139173A1 (fr) 2017-03-08
US8252544B2 (en) 2012-08-28
CN107015009A (zh) 2017-08-04
EP2122363A2 (fr) 2009-11-25
CN107015009B (zh) 2020-11-03
DE102007010834A1 (de) 2008-09-04
CN101636657A (zh) 2010-01-27
ES2620392T3 (es) 2017-06-28
JP5584473B2 (ja) 2014-09-03
US20100143953A1 (en) 2010-06-10
EP2122363B1 (fr) 2017-01-04
WO2008106938A2 (fr) 2008-09-12
JP2010520442A (ja) 2010-06-10

Similar Documents

Publication Publication Date Title
WO2008106938A3 (fr) Diagnostic et stratification des risques d'une insuffisance cardiaque au moyen de peptides natriurétiques pour des patients nyha i
WO2007131031A3 (fr) Procédés de diagnostic d'une maladie pulmonaire et/ou cardiovasculaire
RU2016112154A (ru) Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений
EP3399315A3 (fr) Biomarqueurs dans la sélection du traitement d'une insuffisance cardiaque
WO2009129454A3 (fr) Prédiction du risque d’évènements cardiaques indésirables majeurs
EP2111552B1 (fr) Diagnostic et stratification des risques au moyen du nouveau marqueur ct-proadm
JP2010536012A5 (fr)
WO2011012268A8 (fr) Utilisation d'une protéine mimecan pour évaluer une insuffisance cardiaque
Ramasamy Biochemical markers in acute coronary syndrome
PL1625163T3 (pl) Sposoby wykrywania proBMP przeciwciałem monoklonalnym wiążącym się z aminokwasami 38-43
JP2014514536A5 (fr)
JP2010513879A5 (fr)
Prontera et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study
WO2008135038A3 (fr) DIAGNOSTIC ET STRATIFICATION DU RISQUE AU MOYEN DE NT-proET-1
WO2008049422A3 (fr) Stratification des risques du syndrome coronarien aigu au moyen de fragments et de peptides partiels de la provasopressine, en particulier de la copeptine ou de la neurophysine ii
RU2014145259A (ru) Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
WO2010106347A8 (fr) Marquage biomoléculaire utilisant des analogues multifonctionnels de biotine
SI1664769T1 (sl) Preizkus za detektiranje atrijskih in moĹľganskih natriuretskih peptidnih prohormonov
ATE470862T1 (de) Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten
JP2010511877A5 (fr)
DE602006003411D1 (de) Verwendung von Herzhormonen zur Diagnose des Kardiovaskuläre Risikos als folge einer Verabreichung von Entzündungshemmern
ES2641912T3 (es) Uso de procalcitonina (PCT) en el pronóstico después de síndromes coronarios agudos
RU2014107752A (ru) Среднерегиональный предшественник предсердного натрийуретического пептида (pro-anp) для идентификации пациентов с фибрилляцией предсердий, начавшейся меньше, чем 48 часов тому назад
WO2009138466A3 (fr) Nouveaux polypeptides apparentés à des peptides natriurétiques de type b et leurs procédés d'identification et d'utilisation
Ibarrola et al. Receptor Downstream Targets as Novel Therapeutic Targets

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880006990.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08734336

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1642/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009551101

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2008734336

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008734336

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12529365

Country of ref document: US